01 1Lianhe Aigen Pharma Co., Ltd.
01 1Novartis Korea
01 1Remibrutinib
01 1Blank
Registrant Name : Novartis Korea
Registration Date : 2026-04-14
Registration Number : Su196-35-ND
Manufacturer Name : Lianhe Aigen Pharma Co., Ltd...
Manufacturer Address : No.3 Donghai 8th Avenue, Toumengang New District, Linhai, Taizhou, Zhejiang, 317016, ...
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
17
PharmaCompass offers a list of Remibrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Remibrutinib manufacturer or Remibrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Remibrutinib manufacturer or Remibrutinib supplier.
A Remibrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remibrutinib, including repackagers and relabelers. The FDA regulates Remibrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remibrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Remibrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Remibrutinib supplier is an individual or a company that provides Remibrutinib active pharmaceutical ingredient (API) or Remibrutinib finished formulations upon request. The Remibrutinib suppliers may include Remibrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Remibrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Remibrutinib Drug Master File in Korea (Remibrutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Remibrutinib. The MFDS reviews the Remibrutinib KDMF as part of the drug registration process and uses the information provided in the Remibrutinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Remibrutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Remibrutinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Remibrutinib suppliers with KDMF on PharmaCompass.
